Latest research on G-CSF

Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue manufactured by recombinant DNA technology using a strain of E. coli. It is marketed as the brand name Neupogen by Amgen. Chemically, it consists of 175 amino acid residues. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine necessary for expression in E coli. Tbo-filgrastim, which is marketed by Sicor Biotech and FDA approved on August 29, 2012, contains the same active ingredient as Neupogen and is biologically similar, but it is formulated to be short-acting. On March 6, 2015, the FDA approved the biosimilar Zarxio (filgrastim-sndz) and is indicated for use in the same conditions as Neupogen. Zarxio is marketed by Sandoz.

G-CSF side effects

The aims of this study were to analyze the causes of stranding in a large population of loggerhead turtles admitted to the Tafira Wildlife Rehabilitation Center (TWRC) in Gran Canaria Island, Spain, from 1998 to 2014 using specific epidemiological data, to compare these results with those obtained in other geographic regions, and to analyze the outcomes of the rehabilitation process to allow meaningful auditing of its quality. [source, 2016]
In 2 of 3 replicate experiments, RSV-A2 infection was also associated with significant increase in the apical release of IL-6 (p = 0.0003) and G-CSF (p = 0.006)). [source, 2016]
There was a statistically significant increase in myeloid differentiation as assessed by the expression of F4/80 in the presence of IL3 alone upon Nfix expression, which was further enhanced in the presence of the myeloid-permissive cytokine G-CSF (Fig. 5E and F). [source, 2015]
Coincidently, the resistant population used for the experiment of heritability was collected in the Gran Chaco region, where it can be seen that the LD50 value increased from 54.23 (parental) to 121.93 (F2) and 1455.32 (F3) (Table 2). [source, 2015]
Erythropoietin and Granulocyte Colony Stimulating Factor (GCSF) were applied if the patients’ hemoglobin level or Neutrophil counts decreased under 7 g/dL or 500/mL, respectively. [source, 2015]
Based on a 2-year 20 % increase in event-free survival, anti-GD2 disialoganglioside antibody in combination with interleukin-2 (IL-2) and Granulocyte Colony Stimulating Factor (GM-CSF) has been added to standard of care protocols [3]. [source, 2015]
In addition, the frequent use of G-CSF (about half) in these patients may have improved outcomes because of reduced duration of neutropenia. [source, 2015]
HUS patients also show increased levels of monocyte chemotactic protein-1 (MCP-1), IL-8, macrophage inflammatory protein-1β (Mip-1β) and Granulocyte Colony Stimulating Factor (G-CSF) [15]. [source, 2015]
Serum samples obtained from dexamethasone/CCl4-treated mice expressed decreased levels of the IL-12p40p70 (0.30 ± 0.01 fold; p = 0.0007), G-CSF (0.51 ± 0.02 fold; p = 0.0101) and KC (0.67 ± 0.00 fold; p = 0.0238) as compared to PBS/CCl4 group. [source, 2015]
Although the traditional Chinese medicine Angelicae sinensis is commonly used to promote erythropoiesis for the treatment of anemia, and FA has previously been demonstrated to increase the levels of EPO and G-CSF (8,9), the results of the present study suggest that the neuroprotective effect of FA is not associated with G-CSF. [source, 2015]